Mirum Pharmaceuticals (MEX:MIRM) FCF Margin %: -149.75% (As of Mar. 2026)


MEX:MIRM Mirum Pharmaceuticals Inc MEX:MIRM
46 GF Score
Price MXN1,256.12
GF Value MXN812.06
! 5 Warning Signs
View Full Analysis

What is Mirum Pharmaceuticals FCF Margin %?

Mirum Pharmaceuticals MEX:MIRM 46 FCF Margin % is -149.75% as of Mar. 2026. GuruFocus rates MEX:MIRM with a GF Score™ of 46/100 and a GF Value™ of MXN812.06. The stock has 5 warning signs investors should review. Among 949 Biotechnology companies, Mirum Pharmaceuticals ranks better than 59.01% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Mirum Pharmaceuticals's Free Cash Flow for the three months ended in Mar. 2026 was MXN-4,318 Mil. Mirum Pharmaceuticals's Revenue for the three months ended in Mar. 2026 was MXN2,883 Mil. Therefore, Mirum Pharmaceuticals's FCF Margin % for the quarter that ended in Mar. 2026 was -149.75%.

As of today, Mirum Pharmaceuticals's current FCF Yield % is -2.45%.

The historical rank and industry rank for Mirum Pharmaceuticals's FCF Margin % or its related term are showing as below:

MEX:MIRM' s FCF Margin % Range Over the Past 10 Years
Min: -793.09   Med: -48.85   Max: 10.53
Current: -30.7

During the past 8 years, the highest FCF Margin % of Mirum Pharmaceuticals was 10.53%. The lowest was -793.09%. And the median was -48.85%.

MEX:MIRM's FCF Margin % is ranked better than
59.01% of 949 companies
in the Biotechnology industry
Industry Median: -82.65 vs MEX:MIRM: -30.70

Mirum Pharmaceuticals FCF Margin % Related Terms

Mirum Pharmaceuticals FCF Margin % Historical Data

* Premium members only.

The historical data trend for Mirum Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mirum Pharmaceuticals FCF Margin % Chart

Mirum Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial -793.09 -156.26 -48.85 -3.17 10.53

Mirum Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.79 9.32 29.69 3.67 -149.75

MEX:MIRM vs RYTM, SYRE, PTGX: FCF Margin % Comparison

For the Biotechnology subindustry, Mirum Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mirum Pharmaceuticals FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mirum Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Mirum Pharmaceuticals's FCF Margin % falls into.


MEX:MIRM
46GF Score
Mirum Pharmaceuticals Inc MEX:MIRM
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mirum Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Mirum Pharmaceuticals's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=988.027/9386.587
=10.53 %

Mirum Pharmaceuticals's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-4317.516/2883.104
=-149.75 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -149.75% mean?
Mirum Pharmaceuticals (MEX:MIRM) has a FCF Margin % of -149.75% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Mirum Pharmaceuticals and its competitors. According to the industry distribution chart, Mirum Pharmaceuticals ranks #389 out of 949 companies in the Biotechnology industry, placing it in the top 41%.
Is Mirum Pharmaceuticals' FCF Margin % too high?
Mirum Pharmaceuticals' current FCF Margin % is -149.75%. Based on the distribution chart, Mirum Pharmaceuticals ranks #389 out of 949 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Mirum Pharmaceuticals has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Mirum Pharmaceuticals' FCF Margin % compare to RYTM and SYRE?
According to the Biotechnology industry distribution chart, Mirum Pharmaceuticals ranks #389 out of 949 companies for FCF Margin %. This puts Mirum Pharmaceuticals in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Mirum Pharmaceuticals and its competitors. Mirum Pharmaceuticals's current FCF Margin % is -149.75%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mirum Pharmaceuticals stock overvalued right now?
Mirum Pharmaceuticals (MEX:MIRM) has a current FCF Margin % of -149.75%. The stock's GF Value™ is MXN812.06, compared to a current price of MXN1,256.12 — trading 54.7% above its estimated fair value. The current FCF Margin % is -149.75%. Mirum Pharmaceuticals' overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Mirum Pharmaceuticals (MEX:MIRM), the current FCF Margin % is -149.75% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mirum Pharmaceuticals (MEX:MIRM) Overvalued in 2026?

Based on GuruFocus' analysis, Mirum Pharmaceuticals stock appears to be overvalued. The current stock price of MXN1,256.12 is trading 54.7% above its estimated GF Value™ of MXN812.06.

Key valuation signals for MEX:MIRM:

  • FCF Margin %: -149.75%
  • GF Value™: MXN812.06 vs. price of MXN1,256.12 (54.7% above fair value)
  • GF Score™: 46/100 with 5 warning signs

No single metric tells the full story. See the MEX:MIRM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mirum Pharmaceuticals Business Description

Other Exchanges MIRM:USA08D:Germany
Address 989 East Hillsdale Boulevard, Suite 300, Foster City, CA, USA, 94404
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
46GF Score

Get the complete analysis for MEX:MIRM

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,256.12
Price
MXN812.06
GF Value